NCT00082966View on ClinicalTrials.gov

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2007

Conditions
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma
Interventions
DRUG

17-N-allylamino-17-demethoxygeldanamycin/bortezomib

Given IV

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00082966 - Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter